Table 3 Adverse events that caused a change in dose or treatment switch for patients receiving imatinib, nilotinib and dasatinib
From: A multicenter real-world evidence study in the Swiss treatment landscape of chronic myeloid leukemia
Imatinib | Nilotinib | Dasatinib | Total TKIsa | |
|---|---|---|---|---|
Any adverse event with clinical impact | 17 | 31 | 23 | 79 |
Events in 100 PTY | 25.1 | 30.6 | 45.2 | 33.9 |
Reason for dose adjustment/treatment switch, n | ||||
Hematologic abnormalities | 1 | 6 | 11 | 21 |
Events in 100 PTY | 1.5 | 5.9 | 21.6 | 9.0 |
Gastrointestinal events | 5 | 1 | 0 | 11 |
Events in 100 PTY | 7.4 | 1.0 | 0 | 4.7 |
Pancreatic, renal, liver events | 1 | 9 | 0 | 11 |
Events in 100 PTY | 1.5 | 8.9 | 0 | 4.7 |
Oedema and fluid retention | 3 | 1 | 6 | 10 |
Events in 100 PTY | 4.4 | 1.0 | 11.8 | 4.3 |
Muscle skeletal joint | 3 | 3 | 2 | 8 |
events in 100 PTY | 4.4 | 3.0 | 3.9 | 3.4 |
Cardiovascular events | 0 | 5 | 1 | 6 |
Events in 100 PTY | 0 | 4.9 | 2.0 | 2.6 |
Skin, mucosal events | 2 | 3 | 0 | 5 |
Events in 100 PTY | 3.0 | 3.0 | 0 | 2.1 |
Pleural effusion | 0 | 0 | 4 | 4 |
Events in 100 PTY | 0 | 0 | 7.9 | 1.7 |
Pancreatic events | 0 | 4 | 0 | 4 |
Events in 100 PTY | 0 | 3.9 | 0 | 1.7 |
Hepatic events | 0 | 3 | 0 | 4 |
Events in 100 PTY | 0 | 3.0 | 0 | 1.7 |
Metabolism, homeostasis | 1 | 2 | 1 | 4 |
Events in 100 PTY | 1.5 | 2.0 | 2.0 | 1.7 |
Renal events | 1 | 2 | 0 | 3 |
Events in 100 PTY | 1.5 | 2.0 | 0 | 1.3 |
Other events of interest | 0 | 1 | 2 | 3 |
Events in 100 PTY | 0 | 1.0 | 3.9 | 1.3 |